



September 28, 2010

Centers for Disease Control and Prevention (CDC) Model Performance Evaluation Program for *Mycobacterium tuberculosis* and Nontuberculous Mycobacteria Drug Susceptibility Testing (MTB NTM DST)

Subject: Preliminary Report for Panel Shipped May 17-18, 2010

Dear Participant:

Attached you will find the preliminary susceptibility testing results for the cultures of *M. tuberculosis complex* (MTBC) sent to you May 17-18, 2010. These preliminary results were determined by the candidate reference laboratories and may not represent the consensus of all participants. Although the CDC recommends the radiometric method for routine MTBC drug susceptibility testing, this preliminary report provides the results used in the conventional (agar proportion) method except in the case of pyrazinamide. Participants should use the equivalent radiometric concentrations to determine their results.

This preliminary report will provide you with timely information about the cultures sent to your laboratory. A detailed aggregate report of susceptibility testing results and methods reported by all participants for this panel of five (5) MTBC isolates will be emailed to you before the next scheduled shipment. For additional information or to comment on this report, you may contact Sandra Neal at 1-888-465-6062 or 404 498-2238 or sneal@cdc.gov or contact Beverly Metchock at 404 639-1285 or BMetchock@cdc.gov.

We appreciate your support and participation in the Model Performance Evaluation Program (MPEP) for *Mycobacterium tuberculosis* and Nontuberculous Mycobacteria Drug Susceptibility Testing (MTB NTM DST).

Sincerely yours,

Sandra W. Neal, B.S., MS, MT(ASCP), P.M.P.
Project Officer
NCEZID/DPEI
Centers for Disease Control and Prevention
Ph : 404 498-2238 Fax : 404 498-2215
email : sneal@cdc.gov

Preliminary Report

**Susceptibility Testing Results:
M. tuberculosis Isolates
Panel Shipment May 17-18, 2010**

STRAIN	DRUG RESISTANCE
T	Resistant to RIF @ 1µg/ml and to CIP and OFL @ 2µg/ml
W	Resistant to RIF@ 1µg/ml and to RBT @0.25µg/ml
X	Resistant to INH @ 0.2µg/ml
Y	Resistant to PZA @ 100µg/ml
Z	Susceptible to all first- and second-line drugs